Natalizumab discontinuation in the increasing complexity of multiple sclerosis therapy

Neurology

Volumn 82, Issue 17, 2014, Pages 1484-1485

  Sormani, Maria Pia ^a   De Stefano, Nicola ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; FINGOLIMOD; GLATIRAMER; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; NATALIZUMAB; PLACEBO; VIRUS ANTIBODY;

DISEASE ACTIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDITORIAL; HUMAN; JC VIRUS; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RECURRENT DISEASE; RELAPSE; RISK REDUCTION; TREATMENT WITHDRAWAL;

ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MULTIPLE SCLEROSIS;

EID: 84902184272     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000369     Document Type: Editorial

References (10)

1. Polman CH, O'Connor PW, Havrdova E, et al A randomized, placebo controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354:899-910.
2. Rudick RA, Stuart WH, Calabresi P.A., et al Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354:911-923.
3. Tyler KL. Progressive multifocal leukoencephalopathy: can we reduce risk in patients receiving biological immuno-modulatory therapies? Ann Neurol 2010; 68:271-274.
4. Fox RJ, Rudick RA Risk stratification and patient counseling for natalizumab in multiple sclerosis. Neurology 2012; 78:436-437.
5. Gorelik L, Lerner M, Bixler S., et al Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010; 68:295-303.
6. Fox RJ, Cree BAC, De Séze J, et al. MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology 2014; 82:1491-1498.
7. O'Connor P.W., Goodman A, Kappos L., et al Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 2011; 76: 1858-1865.
8. Gobbi C, Meier DS, Cotton F, et al Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial. BMC Neurol 2013; 13: 101-107.
9. Rinaldi F, Seppi D, Calabrese M., Perini P, Gallo P. Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings. Mult Scler 2012; 18: 1640-1643.
10. Kappos L. Disease control and safety in relapsing-remitting multiple sclerosis (RRMS) patients switching from natalizu-mab to fingolimod: a 32-week, rater- and patient-blind, randomized, parallel-group study (TOFINGO). Presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), October 2-5, 2013, Copenhagen.